title: [Immune reconstitution inflammatory syndrome related with infliximab interruption in patient with Crohn's disease and active tuberculosis].
abstract: Tumor necrosis factor alpha inhibitors are associated with an increased risk of active tuberculosis. However, its interruption in this setting may trigger a paradoxical response to tuberculosis treatment, as an immune reconstitution inflammatory syndrome. We present the case of a 36-year-old patient, with Crohn's disease, treated with infliximab for the last 8 years, who was admitted with miliary tuberculosis. A pan-susceptible Mycobacterium tuberculosis strain was isolated. Infliximab was interrupted and standard antituberculous therapy was started, as well as systemic corticotherapy, without any clinical or radiological improvement. After exclusion of other opportunistic infections and primary or acquired immunodeficiency, we considered the possibility of an immune reconstitution inflammatory syndrome triggered by infliximab interruption. Thus, infliximab was reintroduced after 2 months of antituberculous therapy and clinical and radiological improvement was observed.
authors.forename: J
authors.initials: J
authors.lastname: Carvalho
authors.forename: C
authors.initials: C
authors.lastname: Gonçalves
authors.forename: L
authors.initials: L
authors.lastname: Duque
authors.forename: P
authors.initials: P
authors.lastname: Brito
authors.forename: J
authors.initials: J
authors.lastname: Poças
mesh_terms: D000328:Adult; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000209:etiology*; D000069285:Infliximab / Q000008:administration & dosage*; D008297:Male; D014391:Tuberculosis, Miliary / Q000150:complications
chemical_list: D000069285:Infliximab